AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24525690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 22357383 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet stripping endothelial keratoplasty (DSEK)
Number of subjects: 69
Study 22357383 — intervention group
Group type: EXPERIMENTAL
Intervention: Penetrating keratoplasty
Number of subjects: 69
Study 22357383 — intervention group
Group type: COMPARATOR
Intervention: Normal corneas (control group)
Number of subjects: 69
Study 22357383 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneas without visible subbasal nerves (after DSEK)
Number of subjects: 69
Study 20660020 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 17
Study 20660020 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 17
Study 17660186 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin delta
Number of subjects: 560
Study 17660186 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa
Number of subjects: 560
Study 15718405 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTN3 577X genotype (XX)
Number of subjects: 355
Study 15718405 — intervention group
Group type: COMPARATOR
Intervention: ACTN3 wild type (RR)
Number of subjects: 355
Study 15718405 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTN3 genotype
Number of subjects: 355
Study 12131931 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 2 mg/day for 6 weeks
Number of subjects: 18
Study 9924158 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin treatment to maintain activated clotting time of >300 seconds
Number of subjects: 39
Study 7593733 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide treatment
Number of subjects: 651
Study 2271264 — intervention group
Group type: EXPERIMENTAL
Intervention: False positive results group
Number of subjects: 56
Study 2271264 — intervention group
Group type: COMPARATOR
Intervention: Control group (negative test results)
Number of subjects: 56
Study 368535 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen 1600 mg daily
Number of subjects: 20
Study 368535 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin 100 mg daily
Number of subjects: 20
Study 368535 — intervention group
Group type: EXPERIMENTAL
Intervention: indomethacin and ibuprofen
Number of subjects: 20
Study 31854221 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision along the distal border of the pronator quadratus (Group A)
Number of subjects: 110
Study 31854221 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachioradialis splitting method (Group B)
Number of subjects: 110
Study 30345954 — intervention group
Group type: EXPERIMENTAL
Intervention: DentalVibe
Number of subjects: 150
Study 30345954 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual stimulation
Number of subjects: 150
Study 30345954 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (control)
Number of subjects: 150
Study 27919222 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch (30 min) plus SOC
Number of subjects: 468
Study 27919222 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 8% patch (60 min) plus SOC
Number of subjects: 468
Study 27919222 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 468
Study 22206410 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol, midazolam, dexmedetomidine (BMD)
Number of subjects: 40
Study 22206410 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol, midazolam, propofol (BMP)
Number of subjects: 40
Study 21887594 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet containing 600 g/kg DM of wheat middlings (WM)
Number of subjects: 40
Study 21887594 — intervention group
Group type: COMPARATOR
Intervention: Control diet containing 400 g/kg DM of corn
Number of subjects: 40
Study 21034938 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look procedures (SLP) before completing chemotherapy
Number of subjects: 73
Study 21034938 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look procedures (SLP) during treatment
Number of subjects: 73
Study 21034938 — intervention group
Group type: COMPARATOR
Intervention: No second-look procedures (SLP) during treatment
Number of subjects: 73
Study 18551889 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg daily for 3 days prior to quit date, then 50 mg daily for 8 weeks)
Number of subjects: 110
Study 18551889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 16156143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral injection of 2% hydroxypropyl methylcellulose (HPMC) during trabeculectomy (group II; n = 15)
Number of subjects: 30
Study 16156143 — intervention group
Group type: COMPARATOR
Intervention: Conventional trabeculectomy without HPMC injection (group I; n = 15)
Number of subjects: 30
Study 12116727 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice
Number of subjects: 160
Study 12116727 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (containing copolymer)
Number of subjects: 160
Study 12116727 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer dentifrice (in subgroup with >= 40 bleeding sites)
Number of subjects: 160
Study 11081003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibro-Fit program (interdisciplinary group education and exercise program with 36 sessions over 12 weeks)
Number of subjects: 149
Study 11081003 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibro-Fit program
Number of subjects: 149
Study 8826928 — intervention group
Group type: EXPERIMENTAL
Intervention: Good steroid response
Number of subjects: 184
Study 8826928 — intervention group
Group type: EXPERIMENTAL
Intervention: T-ALL treatment protocols (8303, 8503-8703, and '88)
Number of subjects: 184
Study 8826928 — intervention group
Group type: EXPERIMENTAL
Intervention: T-ALL patients
Number of subjects: 184
Study 8826928 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor in vivo steroid response
Number of subjects: 184
Study 8826928 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte level count > 50 x 10^9/l
Number of subjects: 184
Study 2124962 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V 1000 mg once daily
Number of subjects: 142
Study 2124962 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 250 mg four times daily
Number of subjects: 142
Study 2124962 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 500 mg twice daily
Number of subjects: 142
Study 6770291 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study 31164178 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 60
Study 31164178 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study 28535624 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography (EIT)
Number of subjects: 121
Study 28535624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 121
Study 28535624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 121
Study 28535624 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT combined with Ultrasound
Number of subjects: 121
Study 28535624 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT combined with Mammography
Number of subjects: 121
Study 24983892 — intervention group
Group type: EXPERIMENTAL
Intervention: N-DMT intervention
Number of subjects: 19
Study 24983892 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 19
Study 23190588 — intervention group
Group type: COMPARATOR
Intervention: Diet modification (N = 118)
Number of subjects: 439
Study 23190588 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (N = 117)
Number of subjects: 439
Study 23190588 — intervention group
Group type: COMPARATOR
Intervention: Diet + exercise (N = 117)
Number of subjects: 439
Study 23190588 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 87)
Number of subjects: 439
Study 21518711 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia permission/assent process
Number of subjects: 194
Study 21518711 — intervention group
Group type: COMPARATOR
Intervention: Paper permission/assent process
Number of subjects: 194
Study 21518711 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia parental permission/assent process
Number of subjects: 194
Study 21518711 — intervention group
Group type: EXPERIMENTAL
Intervention: Video version of dual-energy radiograph absorptiometry description
Number of subjects: 194
Study 21518711 — intervention group
Group type: COMPARATOR
Intervention: Animated and paper versions combined for dual-energy radiograph absorptiometry description
Number of subjects: 194
Study 21518711 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia abdominal ultrasound description
Number of subjects: 194
Study 21518711 — intervention group
Group type: COMPARATOR
Intervention: Animated and paper versions combined for abdominal ultrasound description
Number of subjects: 194
Study 21518711 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of study procedures
Number of subjects: 194
Study 21518711 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of risks
Number of subjects: 194
Study 19389417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained convergence for 5 minutes
Number of subjects: 0
Study 16516602 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril at a target dose of 60 mg/day
Number of subjects: 21
Study 16516602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 14722602 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotapes
Number of subjects: 70
Study 14722602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no audiotapes)
Number of subjects: 70
Study 14722602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 11095454 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone at bedtime
Number of subjects: 0
Study 11095454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9050888 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (oral administration)
Number of subjects: 0
Study 9050888 — intervention group
Group type: COMPARATOR
Intervention: GSH deficiency in CD4 T cells
Number of subjects: 0
Study 7914959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuprophane membranes
Number of subjects: 52
Study 7914959 — intervention group
Group type: COMPARATOR
Intervention: Polyacrylonitrile membranes
Number of subjects: 52
Study 3056288 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (34.5 Gy, divided into 15 daily doses of 2.3 Gy each)
Number of subjects: 466
Study 3056288 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative radiotherapy)
Number of subjects: 466
Study 28885279 — intervention group
Group type: EXPERIMENTAL
Intervention: reduced Cardiac Rehabilitation Program (rCRP)
Number of subjects: 121
Study 28885279 — intervention group
Group type: COMPARATOR
Intervention: standard Cardiac Rehabilitation Program (sCRP)
Number of subjects: 121
Study 26201299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir 10 mg once a day
Number of subjects: 243
Study 26201299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir 30 mg once a day
Number of subjects: 243
Study 26201299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir 60 mg once a day
Number of subjects: 243
Study 26201299 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz 600 mg once a day with dual NRTIs
Number of subjects: 243
Study 26201299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir (all doses combined)
Number of subjects: 243
Study 26201299 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (control)
Number of subjects: 243
Study 23592605 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg ropivacaine + 5 µg sufentanil
Number of subjects: 68
Study 23592605 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ropivacaine + 5 µg sufentanil
Number of subjects: 68
Study 23592605 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine + 5 µg sufentanil
Number of subjects: 68
Study 23592605 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg ropivacaine + 5 µg sufentanil
Number of subjects: 68
Study 23592605 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ropivacaine
Number of subjects: 68
Study 20872345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse high-volume hemofiltration (PHVHF) for 72 hours
Number of subjects: 22
Study 20872345 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 22
Study 17707902 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents of HIV-infected mothers
Number of subjects: 105
Study 17707902 — intervention group
Group type: COMPARATOR
Intervention: Adolescents of HIV-uninfected mothers
Number of subjects: 105
Study 17707902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of adolescents
Number of subjects: 105
Study 16651301 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV Information Sheet
Number of subjects: 1600
Study 16651301 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline paragraph about HPV)
Number of subjects: 1600
Study 12783932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg/day
Number of subjects: 120
Study 12783932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg/day
Number of subjects: 120
Study 12783932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day
Number of subjects: 120
Study 12783932 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized control groups (ER-negative breast cancer and additional ER-positive breast cancer)
Number of subjects: 120
Study 12783932 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (all doses)
Number of subjects: 120
Study 10963196 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance cholangiopancreatography (MRCP)
Number of subjects: 124
Study 10963196 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 124
Study 8916481 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of exercise training (interval exercise with bicycle ergometer 15 minutes 5 times weekly, interval treadmill walking 10 minutes, and exercises 20 minutes, each 3 times weekly)
Number of subjects: 18
Study 1760710 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying 5 kg or more weights
Number of subjects: 20
Study 1760710 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrying 10 kg weights
Number of subjects: 20
Study 1760710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild claudicants
Number of subjects: 20
Study 1760710 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe claudicants
Number of subjects: 20
Study 1760710 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight carried (0, 2.5, 5, 7.5, 10 kg)
Number of subjects: 20
Study 7064017 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (40 mg/m2) and cyclophosphamide (700 mg/m2) administered as pulse doses once every 3 weeks.
Number of subjects: 24
Study 7064017 — intervention group
Group type: EXPERIMENTAL
Intervention: Celestin tubes insertion (all patients).
Number of subjects: 24
Study 31927549 — intervention group
Group type: EXPERIMENTAL
Intervention: Group TPVB (20 mL of 0.25% ropivacaine)
Number of subjects: 74
Study 31927549 — intervention group
Group type: COMPARATOR
Intervention: Group LAI (40 mL of 0.25% ropivacaine)
Number of subjects: 74
Study 31927549 — intervention group
Group type: EXPERIMENTAL
Intervention: Group TPVB
Number of subjects: 74
Study 31927549 — intervention group
Group type: COMPARATOR
Intervention: Group LAI
Number of subjects: 74
Study 30859959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 60mg (ITI-007)
Number of subjects: 1783
Study 30859959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 40mg (ITI-007)
Number of subjects: 1783
Study 30859959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 20mg (ITI-007)
Number of subjects: 1783
Study 30859959 — intervention group
Group type: COMPARATOR
Intervention: Risperidone 4mg (active control)
Number of subjects: 1783
Study 30859959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone (open-label safety switching study)
Number of subjects: 1783
Study 30859959 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SOC) antipsychotics
Number of subjects: 1783
Study 28914245 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant mix
Number of subjects: 40
Study 28914245 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 40
Study 26071228 — intervention group
Group type: EXPERIMENTAL
Intervention: Single haemodialysis session
Number of subjects: 28
Study 23782126 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg/day BH4
Number of subjects: 46
Study 23782126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21719096 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg, maximum 1000 mg per dose) administered intravenously on days 1, 14, 28, and monthly for a total of 27 infusions over 2 years
Number of subjects: 112
Study 21719096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 21719096 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 112
Study 19302899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 659
Study 19302899 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 659
Study 19302899 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl IR 10 mg
Number of subjects: 659
Study 19302899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 659
Study 17164971 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of assisted exercise (daily passive extension and flexion range-of-motion exercise of the upper and lower extremities)
Number of subjects: 16
Study 17164971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16
Study 17164971 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of assisted exercise
Number of subjects: 16
Study 17164971 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 14749894 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 19
Study 14749894 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 19
Study 11843769 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit with leukocyte-depleting arterial line filter (HF group)
Number of subjects: 30
Study 11843769 — intervention group
Group type: COMPARATOR
Intervention: Conventional circuit and arterial line filter (C group)
Number of subjects: 30
Study 9669012 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation (PPV)
Number of subjects: 164
Study 9669012 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous ventilation (SV)
Number of subjects: 164
Study 7623530 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase (two boluses of 10 MU given 30 min apart)
Number of subjects: 6010
Study 7623530 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (1.5 MU intravenously over 60 min)
Number of subjects: 6010
Study 7623530 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 6010
Study 7623530 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 6010
Study 2691421 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic nitrous oxide
Number of subjects: 0
Study 2691421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1090193 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 76
Study 1090193 — intervention group
Group type: EXPERIMENTAL
Intervention: imipramine
Number of subjects: 76
Study 1090193 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 76
Study 31619250 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Community-Based Health Systems Strengthening (ICBHSS) initiative
Number of subjects: 21
Study 31619250 — intervention group
Group type: COMPARATOR
Intervention: Stepped-wedge cluster randomized control trial
Number of subjects: 21
Study 31619250 — intervention group
Group type: COMPARATOR
Intervention: Annual health facility assessments
Number of subjects: 21
Study 31619250 — intervention group
Group type: COMPARATOR
Intervention: Key informant interviews
Number of subjects: 21
Study 31619250 — intervention group
Group type: COMPARATOR
Intervention: Costing and return-on-investment assessments for each randomized cluster
Number of subjects: 21
Study 28531873 — intervention group
Group type: EXPERIMENTAL
Intervention: IU CBM‐I (active intervention)
Number of subjects: 0
Study 28531873 — intervention group
Group type: COMPARATOR
Intervention: Control CBM‐I (control condition)
Number of subjects: 0
Study 26296595 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARP Academic Asthma Health Education and Counseling Program
Number of subjects: 205
Study 26296595 — intervention group
Group type: COMPARATOR
Intervention: Open Airways for Schools (Non-Academic Program)
Number of subjects: 205
Study 23538293 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill interval-training programs
Number of subjects: 20
Study 23538293 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest intensity uphill interval-training
Number of subjects: 20
Study 23538293 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle intensity uphill interval-training
Number of subjects: 20
Study 22069289 — intervention group
Group type: EXPERIMENTAL
Intervention: vitD3 (140,000 IU monthly)
Number of subjects: 59
Study 22069289 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 59
Study 19413683 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.01 mg min(‐1) IV, max 0.1 mg, placebo SC)
Number of subjects: 9
Study 19413683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (6 mg SC, placebo IV)
Number of subjects: 9
Study 19413683 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl IV and SC)
Number of subjects: 9
Study 17045887 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual thrombus aspiration before standard PPCI
Number of subjects: 148